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Abstract
Background: In 2009, the promulgation of US Food and Drug Administration (FDA) tobacco regulation focused attention on
cigarette flavor additives. The tobacco industry had prepared for this eventuality by initiating a research program focusing
on additive toxicity. The objective of this study was to analyze Philip Morris’ Project MIX as a case study of tobacco industry
scientific research being positioned strategically to prevent anticipated tobacco control regulations.
Methods and Findings: We analyzed previously secret tobacco industry documents to identify internal strategies for
research on cigarette additives and reanalyzed tobacco industry peer-reviewed published results of this research. We
focused on the key group of studies conducted by Phillip Morris in a coordinated effort known as ‘‘Project MIX.’’ Documents
showed that Project MIX subsumed the study of various combinations of 333 cigarette additives. In addition to multiple
internal reports, this work also led to four peer-reviewed publications (published in 2001). These papers concluded that
there was no evidence of substantial toxicity attributable to the cigarette additives studied. Internal documents revealed
post hoc changes in analytical protocols after initial statistical findings indicated an additive-associated increase in cigarette
toxicity as well as increased total particulate matter (TPM) concentrations in additive-modified cigarette smoke. By
expressing the data adjusted by TPM concentration, the published papers obscured this underlying toxicity and particulate
increase. The animal toxicology results were based on a small number of rats in each experiment, raising the possibility that
the failure to detect statistically significant changes in the end points was due to underpowering the experiments rather
than lack of a real effect.
Conclusion: The case study of Project MIX shows tobacco industry scientific research on the use of cigarette additives
cannot be taken at face value. The results demonstrate that toxins in cigarette smoke increase substantially when additives
are put in cigarettes, including the level of TPM. In particular, regulatory authorities, including the FDA and similar agencies
elsewhere, could use the Project MIX data to eliminate the use of these 333 additives (including menthol) from cigarettes.
Please see later in the article for the Editors’ Summary.
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The tobacco industry has been preparing for regulation of its
products since at least 1963 when Philip Morris (PM) Vice President
of Research and Development Helmut Wakeham expressed concern
that the existing US Food and Drug Administration (FDA) ‘‘generally
recognized as safe (GRAS)’’ for food additives would not apply to
cigarettes and observed that, ‘‘Strictly speaking, only published
studies could be used to establish a GRAS list for things which are
inhaled. Relatively few such studies have been made. This concept
would provide a rather formidable barrier in the case of cigarettes’’
[1]. In 1984 the safety of cigarette additives first becamea public issue
in the United States [2]. Additives are important elements of tobacco
products because they allow manufacturers to modify the sensory and
pharmacological properties of tobacco products in a way that affects
initiation and cessation (with additives that make the smoke less harsh
or more pleasant to the user) or bioavailability and impact of nicotine
(through changes in smoke pH or through additives such as menthol)
(Box 1) [3,4]. Regulating additives, including prohibiting their use,
poses a serious threat to the tobacco companies. The threat of
regulation grew in 1995 when President William Clinton allowed the
FDA to regulate cigarettes. While the industry won a Supreme Court
ruling that the FDA did not have authority to regulate tobacco
products, PM executives recognized by the mid-1990s that regulation
was inevitable. They initiated efforts to shape the legislation that
would become the 2009 Family Smoking Prevention and Tobacco
Control Act [5] granting the FDA authority over tobacco products
[6–8]. (Among the first actions taken by the newly established FDA
Center for Tobacco Products in 2009 was prohibition of flavor
additives in cigarettes, with the exceptions of tobacco and menthol
[9].) While US legislation over tobacco product regulation was being
debated, several tobacco companies developed procedures for
assessing the biological effects of new products that delivered nicotine
differently than conventional cigarettes [10]. In addition, tobacco
product regulation became a global issue with development and
implementation of the 2005 World Health Organization (WHO)
Framework Convention on Tobacco Control (FCTC) [11], whose
articles 9, 10, and 11 require parties to regulate tobacco products.
In addition to its political response [6,7], PM USA reorganized
its internal scientific activities to respond to product regulation. In
a July 1997 memo ‘‘1997 FDA Compliance Preparation,’’ PM’s
Vice President of Research and Development stated that, ‘‘It is
important that we quickly … move to prepare ourselves for these
potential regulations’’ [12]. PM had been analyzing smoke
constituents and performing toxicology testing on cigarettes at its
European laboratories for decades [13]. In August 1997 PM began
to plan and conduct studies of the chemical and toxicological
effects of 333 cigarette additives through its ‘‘Project MIX’’ [14].
Project MIX included chemical analysis of smoke, in vitro
mutagenicity and cytotoxicity testing, and in vivo rat inhalation
toxicology studies. The studies resulted in four papers published
together in Food and Chemical Toxicology in January 2002 [15–18].
The overall conclusion reported by PM in these four papers was
that, ‘‘The statistically significant changes detected in some of the
parameters measured in these studies were considered incidental,
without influence on the overall biological effects normally seen
with cigarette smoke exposure. There was no indication of any
new effects that could be attributable to ingredients’’ [15].
The use of cigarette additives is an important concern of the FDA.
Among the first actions taken by the newly established FDA Center
for Tobacco Products in 2009 was prohibition of flavor additives in
cigarettes, with the exceptions of tobacco and menthol [9], and in
2011 the FDA’s Tobacco Products Scientific Advisory Committee
concluded that, ‘‘Removal of menthol cigarettes from the market-
place would benefit public health in the United States’’ [19].
PMhasused thepublished Project MIX papersto assertthesafety
of individual additives, citing the not yet published papers in a 2001
series of white papers. These papers include Evaluation of Menthol for
Use as a Cigarette Ingredient [20] and at least seven others (cocoa [21],
propylene glycol [22], vanilla extract [23], glycerol [24], sweet
orangeoil[25],andlicoriceextract[26]).Lorillardscientist,J.Daniel
Heck, a member of the FDA Tobacco Products Scientific Advisory
Committee [27] cited Project MIX findings in a 2010 review paper
arguing that use of menthol in cigarettes is safe [28].
We used documents made public as a result of litigation against
the tobacco industry to investigate the origins and design of Project
MIX and conducted additional analyses of the results. This
assessment raises questions about the four papers’ conclusion that
the results ‘‘did not demonstrate any meaningful effect of these
[333] ingredients on the toxicity of cigarettes’’ [15].
Methods
Tobacco Industry Documents
We systematically examined tobacco industry documents in the
University of California San Francisco Legacy Tobacco Docu-
ments Library (LTDL; http://legacy.library.ucsf.edu/), which
were discovered using established protocols and methods of
searching documents based on the snowball technique, by which
Box 1. Excerpt from FCTC implementing
guidelines on ingredients (articles 9 and 10)
[3, Section 3.1.2.2].
Ingredients used to increase palatability
Theharshandirritatingcharacteroftobaccosmokeprovides
a significant barrier to experimentation and initial use.
Tobacco industry documents have shown that significant
effort has been put into mitigating these unfavourable
characteristics.Harshnesscanbereducedinavarietyofways
including: adding various ingredients, eliminating subs-
tances with known irritant properties, balancing irritation
alongside other significant sensory effects, or altering the
chemicalproperties oftobacco product emissions byadding
or removing specific substances.
Some tobacco products contain added sugars and
sweeteners. High sugar content improves the palatability
of tobacco products to tobacco users. Examples of sugars
and sweeteners used in these products include glucose,
molasses, honey, and sorbitol.
Masking tobacco smoke harshness with flavours contrib-
utes to promoting and sustaining tobacco use. Examples
of flavouring substances include benzaldehyde, maltol,
menthol, and vanillin.
Spices and herbs can also be used to improve the
palatability of tobacco products. Examples include cinna-
mon, ginger, and mint.
Recommendation:
Parties should regulate, by prohibiting or restricting,
ingredients that may be used to increase palatability in
tobacco products.
Ingredients indispensable for the manufacturing of tobac-
co products and not linked to attractiveness should be
subject to regulation according to national law.
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address our research question about how the tobacco industry uses
scientific research as a strategy to oppose anticipated tobacco
control policy, we began with the search terms ‘‘ingredients,’’
‘‘additives,’’ and ‘‘toxicity.’’ This initial search yielded thousands
of documents, sorted for relevance by the optical character
recognition capability of LTDL on the basis of the number of
times a search term appears in a document. Screening the
documents qualitatively in batches of 50 to 100 helped refine and
narrow the search allowing us to collect documents that would
help construct a history and provide context for the information
that was coming forth. Additional relevant documents were
returned by examining adjacent documents (Bates numbers), and
searching for key individuals mentioned and locations in which
relevant documents were found. The iterative process of searching,
analyzing, and refining led to the identification of Project MIX as
a key search term. We reviewed approximately 500 relevant
documents in detail, including German language documents from
the PM-owned European laboratories where Project MIX was
conducted. Our analysis is necessarily limited only to those
materials (about 60 million pages at the time we conducted this
study) that are available as a result of litigation [29].
Results
Design Elements
Origins of Project MIX. The tobacco companies have a
long history of animal research, dating back to at least the 1960s,
when they attempted to identify and eliminate the chemicals that
caused cancer as part of the effort to develop a ‘‘safe cigarette’’ (see
in [32], Chapter 4). Beginning in the late 1970s, PM scientists
conducted mouse inhalation and skin painting studies to assess
potential cigarette additives, including urea and carmel [33], cocoa
[34], and glycerol [35]. In the 1980s PM routinely performed
chemical analysis of smoke [36,37], cytotoxicity testing (Ames and
neutral red uptake tests) for mutagenicity [38,39], and in vivo
rodent toxicology studies [40–42], honing the techniques for
performing these assays at their Institut fu ¨r Biologische Forschung
(INBIFO) in Germany and Contract Research Center (CRC) in
Belgium [13].
In March 1994 lawyers representing PM (at the Covington &
Burling law firm) commissioned a report on cigarette additives
written by six toxicology experts that concluded ‘‘ingredients are
not hazardous under the conditions of use’’ [43]. A list of 599
ingredients used in the manufacture of cigarettes was made public
for the first time in August 1994 [44] that the industry regarded as
‘‘safe’’ [45]. By 1997 PM joined the Society of Toxicology and the
American College of Toxicology to position PM scientists to
present and publish results of the INBIFO trials and the six
toxicology experts [46].
PM scientists designed Project MIX in 1997 to evaluate the
effects of cigarette additives on smoke chemistry, in vitro
mutagenicity and cytotoxicity, and in vivo biological activity
[14]. In 2001 the four papers written by PM scientists based on the
Project MIX results were accepted for publication in Food and
Chemical Toxicology [15–18] through a process that PM scientist and
leader of Project MIX Edward Carmines described to coworkers
as ‘‘an inside job. We went to a journal whose editor knew us’’
[47].
Carmines’ comment is well founded. The then editor of Food and
Chemical Toxicology, Joseph Borzelleca, was a member of the US
tobacco industry’s Council for Tobacco Research Scientific
Advisory Board [48] and PM Scientific Advisory Board [49] and
had a long history of doing contract research and consulting for
PM (e.g., see [50] and [51]; there are thousands of documents
mentioning Borzelleca in LTDL). The associate editor, P.J. van
Bladeren, was coauthor of a paper at the 1991 meeting sponsored
by Indoor Air International, a group managed by tobacco industry
lawyers, ‘‘International Conference: Priorities for Indoor Air
Research and Action’’ [52] that served as the launch for a
nominally peer-reviewed journal that could be used to publish
research supporting the tobacco industry’s position on secondhand
smoke [53]. Susan Barlow, one of two review editors, coauthored a
PM-funded review paper that, after incorporating comments from
PM, questioned the evidence linking secondhand smoke and
sudden infant death syndrome [54]. Eleven of the journal’s
International Editorial Board members had ties to the tobacco
industry: three were employees (A.W. Hayes, D.J. Doolittle [55–
57], and Y.P. Dragan [58–60]; two held positions on PM Scientific
Advisory Board (M. Pariza and S.L. Taylor [61]); and six others
had tobacco industry funding or other connections (O.I. Aruoma
[62,63], A.R. Boobis [64–66], H.R. Glatt [67–69], G.C. Hard
[70,71], B. Pool-Zobel [72,73],and H. Poulsen [74–77]).
Additive selection. Project MIX examined the potential
chemical and biological effects of 333 additives used in cigarette
manufacturing, selected because they ‘‘are representative of flavors
used throughout the world by Philip Morris’’ [78]. The 333
additives represent some of the 599 that had been reported to be
added in cigarette manufacturing [44].
The 333 additives selected for testing under Project MIX were
divided into three overlapping ‘‘ingredient groups’’ [15]. The
additives were added to tobacco during the cigarette manufactur-
ing process to produce the test cigarettes. The control cigarette
contained tobacco only. Two target levels for each additive, a low
level that ‘‘approximated the level considered to be reflective of
those used in commercial cigarettes’’ [15] and a high level, 1.5 or 3
times multiple of the low level. (The exception was menthol in
ingredient group 3, which was only studied at a single level, 18,000
parts per million [ppm], in both the low and high groups ‘‘because
no more material could be physically incorporated into the test
cigarette’’ [15].) Carmines, et al. state in the published paper [15]
that they could only vary the levels by a factor of 1.5–3 because it
was the maximum amount of the ingredients that the cigarettes
would hold and still ‘‘burn in manner similar to the control
cigarette.’’ Tobacco was removed from the test cigarettes to keep
the cigarette mass constant.
The specific contents of the test cigarettes are listed in tabular
form in the published paper [15] and can be summarized as
follows: ingredient group 1, 177 additives; ingredient group 2, 277
additives (including 117 also in group 1); ingredient group 3,
mostly menthol plus cocoa shells, licorice extract, and corn syrup.
The process or logic for assigning additives to groups is not
evident from the industry documents or published papers. It is not
clear how or why PM selected these 333 additives and the specific
amounts or combinations used, nor why the other 266 were not
selected for testing in Project MIX. The published paper [15]
simply states that the additives are ‘‘representative of ingredients
[additives] used throughout the world,’’ are ‘‘food-grade quality or
better,’’ and were added during the test cigarette manufacturing
process ‘‘to closely mimic the actual process’’ that ‘‘were
constructed to resemble typical commercial blended cigarettes.’’
To prepare for Project MIX, PM USA manufactured seven test
cigarettes under these product codes: 97.MG.292 for control,
97.MG.295 and 97.MG.296 for ingredient group 1 low and high,
97.MJ.125 and 97.MJ.126 for ingredient group 2 low and high,
and 97.MJ.127 and 97.MJ.128 for ingredient group 3 low and
high [79]. The test cigarettes were released to INBIFO in January
Toxic Effects of Cigarette Additives
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performance tests were completed [80].
Chemical analysis of the smoke. INBIFO measured 51
mainstream smoke constituents in the Project MIX test cigarettes.
According to Carmines, these constituents were selected from lists
prepared by the US Consumer Product Safety Commission
(CPSC) [81] and International Agency for Research on Cancer
[16] (IARC) monograph 38 [82]. A 1997 memo written by PM
scientist Rick Solana [83,84] indicates that PM had created a list of
39 as a ‘‘current smoke constituent chemistry list for analyzing
mainstream smoke in product integrity testing’’ on the basis of the
IARC and CPSC lists screened against the 1994 National
Toxicology Program (NTP) carcinogen list.
We could not determine how the 51 constituents were selected
for use in Project MIX. The published paper from Project MIX
[16] acknowledges the selection was ‘‘to a certain degree subjective
and not based on extensive risk assessments,’’ and argues that
some analytes were not included because ‘‘there is no straightfor-
ward toxicological interpretation for changes that might occur’’ or
because ‘‘their method development is still in progress’’ [16].
Combining the CPSC and IARC lists yields 118 compounds (Text
S1, Table S-1). Solana noted (in 1997, of the 39 constituent list),
that ‘‘polyaromatic hydrocarbons…will be kept on the current list
this is due to the focus on this class of compounds. Even these
compounds, however, might be considered for discontinuing
should they prove to consistently track the polyaromatic
hydrocarbons which are on the recommended list’’ [83]. This
decision could account for the omission of some constituents from
Project MIX.
The list of 72 constituents not measured in Project MIX
includes 11 polycyclic aromatic hydrocarbons (PAHs). PAHs are
of particular concern because they cause carcinogenic and
noncarcinogenic disease in animals and in humans [85–87].
Project MIX also included eight chemicals not on the CPSC,
IARC, or National Toxicology Program (NTP) lists: three PAHs:
acenaphthene, acenaphthylene, benzo[ghi]perylene; naphthalene;
m-, o-, and p-cresol; and particle size distribution. One of these
PAHs was also identified in a single ingredient smoke analysis
study, conducted by PM under the code name URSUS in 1994
[88].
Omission of ammonia results. Project MIX assessed
ammonia levels in the smoke of the test cigarettes, yet the results
were not included in the published report [16]. Internal reports
from early 1999 [89,90] show that ammonia was analyzed and
significantly elevated in the smoke from ingredient group 1 high
level and ingredient group 2 low and high levels, and significantly
decreased in ingredient group 3 (containing menthol) low and high
levels, compared to control cigarette smoke (Figure 1). The
omission of ammonia test results from the final reports is curious in
light of the fact that ammonia increases the pH of tobacco smoke
making it less acidic and therefore easier to smoke [91] while
increasing the bioavailability of the nicotine present in the smoke
[92,93]. No pH test results for the Project MIX test cigarettes were
found.
Presentation of Results: Normalizing by Total Particulate
Matter
In October 1998, ‘‘at the request of the client [PM USA]’’ [94],
INBIFO scientists amended the Project MIX study protocol to
report and analyze results on a per total particulate matter (TPM)
basis; the original January 1998 plan [95] called for results to be
presented on a per cigarette basis. The change was made 8 mo
after INBIFO scientist Wolf Reininghaus reported to PM USA
Manager of External Studies Gerry Nixon [96,97] that the Project
MIX ‘‘prototypes differ from control in a 10% higher TPM yield
(which is compensated for by dilution in the subchronic study),
[and] a 20% higher acrolein yield (which is, after compensation for
TPM, no relevant difference)’’ [96].
The published paper does include a table reporting the smoke
chemistry results on a per cigarette basis [16]; these data showed
that all the test cigarettes containing any additives produced more
TPM than the control cigarettes (ingredient group 1 low and high
levels were 15% and 13% higher, ingredient group 2, 17% and
28%, and ingredient group 3, 13% and 16%, higher). Rather than
emphasizing the biological importance of this increase in TPM,
PM’s researchers normalized the results by TPM and discussed
whether the additives increased the amounts of each toxin in the
smoke per unit TPM produced compared to the control cigarettes.
Thus, as long as the amount of a toxin in the smoke of a test
cigarette increased by less than the amount TPM increased in that
cigarette, the ratio would drop even if both the toxin and TPM
increased with the additives.
After TPM normalization, the graphical presentation of results
as radar plots in the published paper [16] shows only five of the 31
toxins increased in ingredient group 1 and 15 showed drops. The
PM scientists concluded, on the basis of this analysis (and similar
analyses for the other two ingredient groups), ‘‘that the addition of
Figure 1. This result from an internal INBIFO report dated
January 1999 shows results for measuring ammonia in Project
MIX [89]. (Error bars are SD.) All three ingredient groups were
associated with increased TPM, higher gas phase ammonia for
ingredient group 1 and lower levels for ingredient groups 2 and 3 (in
a dose-dependent manner), reported as statistically significant [90].
Total ammonia was increased in ingredient groups 1 and 2. Because
cigarettes with the additives produced more TPM, normalizing the
ammonia produced by TPM lowered (and in most cases reversed) the
estimated effects of the ingredients on ammonia production.
doi:10.1371/journal.pmed.1001145.g001
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did not add to the toxicity of smoke, even at the exaggerated levels
tested in the present series of studies’’ [16].
Smokers do not, however, smoke cigarettes to titrate their TPM
exposure. They smoke whole cigarettes, generally to obtain a
certain amount of nicotine [98–100]. Therefore we used PM’s
published results [16] to prepare a corresponding set of radar plots
that present the levels of toxins per cigarette (as a fraction of
control) and the ratio of the levels of toxin per unit nicotine for the
cigarettes with additives compared to the level of toxin per unit
nicotine in the control cigarettes (Figures 2–4). Presenting the
Project MIX results this way provides a much different picture
than that in PM’s paper: On a per cigarette basis, 31 of 51
chemicals increased in at least one of the three ingredient groups
over control (with 17 decreased), and 37 increased (and nine
decreased) on a per unit nicotine basis.
Fifteen chemicals increased by 20% or more above the levels
observed in the control cigarettes (Table 1). These chemicals
include a number of human and animal carcinogens (arsenic,
cadmium, 1,3-butadiene, lead, formaldehyde, and PAHs), respi-
ratory irritants (e.g., acrolein), and cellular toxicants (hydrogen
cyanide, carbon monoxide). The number of smoke constituents
that increase by 20% or more rises from seven constituents when
normalized by TPM to 18 when expressed per cigarette and 23 on
a per nicotine basis. Likewise, 24 chemicals fell by more than a
20% reduction when normalized by TPM (all but nine are on the
published radar plots), compared to 12 on a per cigarette basis and
nine on a per nicotine basis (Figures 2–4).
For unexplained reasons, the paper [16] excluded 19 of the 51
chemicals tested from the radar plots that formed the basis for
discussing the results (Text S1, Table S-2). Two of the excluded
compounds significantly increased in smoke on a per cigarette
basis of additive-added cigarettes, compared to smoke of control
cigarettes, for all ingredient groups: benzo[-]fluoranthenes and
benzo[ghi]perylene, both PAHs. Six more PAHs that were
significantly higher in the smoke from cigarettes of ingredient
groups 2 and 3 were also missing from the published radar plots—
phenanthrene, anthracene, fluoranthene, pyrene, benz[a]anthra-
cene, and chrysene—as well as a seventh, indeno[1,2,3-cd]pyrene,
which was significantly increased in ingredient group 1. (We
include all 51 smoke constituents in our analysis, shown in
Figures 2–4 and Table 1.).
In Vivo Subchronic Inhalation Testing
The in vivo animal toxicology portion of Project MIX consisted
of exposing male and female Sprague-Dawley rats, nose only, to
either fresh air (sham) or diluted mainstream smoke from the
Project MIX control and test cigarettes for 90 d, followed by a 42-
d postexposure period, after which time the animals were
sacrificed and histopathology studies were completed [18]. The
levels of smoke exposure were adjusted to expose all rats to the
same level of TPM (150 mg TPM/l), regardless of which cigarettes
(i.e., control or ingredient group) were used to generate the smoke.
The PM investigators [18] reported a ‘‘few minor differences’’
in the biological activity of the rats exposed to cigarettes with the
additives, but dismissed these differences as ‘‘following no clear
pattern,’’ suggesting they are ‘‘due to statistical inference.’’ The
overall conclusion, reported in the paper’s abstract is that ‘‘the
data [from a 90-d inhalation study] indicate that the addition of
the 333 commonly used ingredients, added to cigarettes in three
groups, did not increase the inhalation toxicity of the smoke.’’
The animal toxicology results [18] reported from Project MIX
were based on a small number of rats in each experiment (usually
nine), raising the possibility that the failure to detect statistically
significant changes in the end points were due to underpowering
the experiments rather than lack of a real effect. To explore this
possibility, we assumed that the published descriptive statistics
(means and standard deviations [SDs]) were unbiased estimates of
the effects of those additives, then examined what the statistical
conclusions would have been had Project MIX found these results
on the basis of a sample size of 50 rats per group rather than nine
rats per group. (While doing the actual experiment with a larger
sample size would likely not yield precisely the same means and
SDs as in the published paper, the differences should be randomly
distributed on the assumption that the reported results are
unbiased). We selected a sample size of 50 because PM used a
much larger sample size of 99 rats (of each gender) in its study
comparing the effects of secondhand smoke with diesel exhaust
[101,102]. When the reported standard error of the mean (SEM)
was 0, we assumed the SD was 0.001. We then computed an
analysis of variance using the reported means and SDs with an n of
50; if this ANOVA was significant (p,0.05), we then conducted
multiple comparisons against control cigarettes with Holm-Sidak t-
tests using a 0.05 family error rate. All calculations were done with
Primer of Biostatistics (version 6) with the n, mean, SD option for
ANOVA [103].
This exercise yielded 194 statistically significant changes
(compared to the 26 reported in PM’s published paper, Text
S1,Table S-3), suggesting that a better powered study would have
detected a much broader range of biological effects associated with
the additives than identified in PM’s published paper [18],
suggesting that it substantially underestimates the toxic potential of
cigarette smoke and additives.
Discussion
The laboratory aspects of Project MIX studies appear to have
been conducted using well-accepted laboratory practices, so the
raw data are probably unbiased. The essential conclusion that the
PM investigators reached, on the basis of these data, that ‘‘The
studies with ingredients added to cigarettes did not demonstrate
any meaningful effect of the ingredients on the toxicity of
cigarettes’’ [15], however, is a reflection of the way that the data
were normalized in the studies of toxins in the smoke [16] and low
power of the animal toxicology studies [18]. Despite these
problems, Project MIX results have been widely promoted to
the scientific community [104–116], the public at large, and the
Institute of Medicine [117], as well as cited by other tobacco
industry scientists [118–122].
The conclusion that the additives did not increase the yield of
toxins in the smoke is a direct result of the fact that the cigarettes
containing the additives produced 15%–28% more TPM than the
control tobacco-only cigarettes. The fact that the additives lead to
more TPM is, itself, an important indicator of increased toxicity
because the TPM in cigarette smoke leads to substantial increases
in risk of cardiovascular disease, with a steep and highly nonlinear
dose-response at low levels of exposure [123–126]. TPM exposure
also disrupts physiological angiogenesis and contributes to ectopic
pregnancy, spontaneous abortion, preterm delivery, sudden infant
death syndrome, and slower wound healing [127].
In a letter to the editor of Food and Chemical Toxicology, Vleeming
et al. [128] also commented on the fact that normalizing toxin
production in smoke gave a misleading picture of the effects of the
additives on smoke toxicity. They suggested that toxin levels
should be normalized by the amount of tobacco in each cigarette.
Since PM reduced the amount of tobacco when including the
additives to maintain the mass of the cigarette constant, presenting
the results normalized by tobacco weight led to even greater
Toxic Effects of Cigarette Additives
PLoS Medicine | www.plosmedicine.org 5 December 2011 | Volume 8 | Issue 12 | e1001145Figure 2. Graphical display of smoke constituents per cigarette and per unit of nicotine compared to control cigarettes for
ingredient group 1. Low levels of additives are open circles, high levels are solid circles. Points outside the circle at 100% indicate increased levels
of smoke constituents; points inside indicate less.
doi:10.1371/journal.pmed.1001145.g002
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our Figures 2–4). The PM researchers justified their use of TPM
normalization on the grounds that ‘‘We choose TPM as our basis
of comparison to be consistent with the animal and in vitro studies
presented in this series of publications’’ and because ‘‘Since
consumers choose to smoke cigarettes according to the tar delivery
Figure 3. Graphical display of smoke constituents per cigarette and per unit of nicotine for ingredient group 2. Low levels of additives
are open circles, high levels are solid circles. Points outside the circle at 100% indicate increased levels of smoke constituents; points inside indicate
less.
doi:10.1371/journal.pmed.1001145.g003
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reveal the effect of ingredients which contribute to the taste’’
[129]. The first of these arguments is surprising since, as noted
above, the original design of Project MIX did not anticipate
reporting and analyzing results normalized by TPM [130] and
only introduced this normalization after PM had results showing
Figure 4. Graphical display of smoke constituents per cigarette and per unit of nicotine for ingredient group 3. Low levels of additives
are open circles, high levels are solid circles. Points outside the circle at 100% indicate increased levels of smoke constituents; points inside indicate
less.
doi:10.1371/journal.pmed.1001145.g004
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was correspondingly less tobacco in the cigarettes). Also, as noted
above, it is well-established that smokers smoke to control the
delivery of nicotine, not tar (TPM) [98–100] and normalizing
toxin deliveries by nicotine delivery yields higher toxicity estimates
than normalizing by TPM (Figures 2–4; Table 1).
The fact that the in vivo toxicology studies [18] were conducted
at matched levels of TPM for the smoke from all cigarettes (to hold
TPM constant) also meant, as PM scientist Reininghaus noted
internally in 1998 [96], that the rats breathing the smoke from the
cigarettes with the additives were exposed to lower levels of toxins
in the smoke than if the exposures had been matched on another
smoke variable, such as nicotine delivery. To the extent that the
mass of tobacco in the cigarette determines nicotine delivery,
Vleeming et al.’s [128] approach suggests that the underestimates
of toxin exposures the rats received compared to human smokers
could be substantial.
Another problem with the in vivo toxicology studies is that PM
exposed the animals to fixed levels of TPM and the ratio of TPM
to gas phase toxins changes with the different ingredient groups. If
the production of gas phase toxins increases less than the increase
in TPM, then exposing the rats to a fixed amount of TPM will
reduce exposure to the gaseous constituents. For physiological
endpoints affected by these gases the toxicity might appear to
decrease on the basis of per TPM versus per cigarette exposures.
Indeed, when PM instructed INBIFO to analyze the smoke
chemistry data on a per TPM basis [94] they noted that such an
adjustment was already ‘‘compensated for by dilution in the
subchronic study’’ [96].
The way the animal toxicology studies were designed with the
relatively short (90 d) exposure period and follow-up after the end
of the exposure (42 d) also raises concerns. PM’s comparison of
secondhand smoke with diesel exhaust (also conducted at INBIFO)
had 99 rats of each gender in each exposure group, exposed the
rats for 24 mo (730 d) with a 6-mo (183 d) follow-up [101,102].
Longer exposure and follow-up would have increased the power of
Project MIX to detect toxic effects of the additives. Even with
these downward biases due to experimental design, however, our
results suggest that an adequately powered design would have
revealed a large number of toxic effects on the rats.
PM conducted extensive research on individual additives; the
industry documents contain a list of 170 projects [131] conducted
between 1973 and 1995 that includes many single additive projects.
These single additive projects include INBIFO Project Juice, in
whichcitricacid(oneofthe 333ingredientsinthepresentstudy)was
added in low (2.6%), medium (3.9%), and high (6.3%) quantities to
cigarette filler [132]. The amounts of citric acid reported for Project
MIX ingredient group 1 were low level=44 ppm, and high
level=122 ppm. It is not clear how these amounts of citric acid
compare across studies. Studies were also conducted with lactic acid
(Project Milk [133]), propylene glycol [134], and cocoa [34]. These
studies were also conducted using low ratios between groups, along
the order of only a 2- to 3-fold difference.
Project MIX also included in vitro genotoxicity and cytotoxicity
studies [17] using a standard test panel PM developed in 1996,
including the Ames test [14,135–137]. Not surprisingly, the results
of these tests found that all of the cigarettes, whether or not they
included additives, were genotoxic and mutagenic. These tests,
however, arescreening tests,notsensitivemeasuresofdose-response
[138–141]. Therefore they are not appropriate for quantifying
changes in toxicity associated with the additives. Absent the unlikely
situation that the additives would eliminate tobacco smoke’s
genotoxicity and mutagenicity, the failure to find increased toxicity
associated with the additives does not support the conclusion that
‘‘in vitro mutagenicity and cytotoxicity of the cigarette smoke were
not increased by the addition of the ingredients’’ [17].
Scientists at British American Tobacco (BAT) conducted a
similar project that in 2004 was also published in Food and Chemical
Toxicology [142–144]. The BAT studies assessed 482 additives in
various mixtures ‘‘at or above their typical maximum levels used on
cigarettes sold by BAT’’ through an analysis of 45 selected smoke
constituents in mainstream smoke of test cigarettes; in vitro
mutagenicity and cytotoxicity tests (Ames test, mammalian cell
micronucleus test, and neutral red uptake test) and 90-d inhalation
studies inmaleandfemaleSprague-Dawley rats(ten ratspergroup).
Using comparable rates of exposure of rats to smoke (approximately
20% less than the PM study rats), the BAT scientists report similar
deleterious histopathological findings as Project MIX: increased
density of goblet cells in respiratory epithelium, increased
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epiglottal metaplasia. Similar to the PM scientists, the BAT
scientists downplayed the findings by concluding that they were
inconsistent, indicating that the response of rats exposed to smoke
was indistinguishable between test and control cigarettes.
The kind of manipulation of the presentation of scientific results
demonstrated by the publication of the Project MIX results [15–
18], is nothing new for the tobacco industry; industry researchers
have a long history of doing so around a variety of issues related to
secondhand smoke [145–149]. While the procedures to collect the
data themselves appear sound, the way that the data were
analyzed and interpreted is not. An important implication of the
analysis we present is that the scientific community and regulatory
authorities cannot take the conclusions in tobacco industry (or
industry-funded) research or research published in industry-
dominated journals such as Food and Chemical Toxicology at face
value. Vigorous implementation of FCTC article 5.3, which seeks
to protect the policy making process against tobacco industry
interference and manipulation [150], underscores the need for
such skepticism in considering research such as Project MIX (and
the corresponding papers from BAT) at face value in the
rulemaking process. It will be important for the US FDA,
WHO, and regulatory agencies in other countries who are
working to implement FCTC articles 9–11 to insist on receiving all
drafts of the study protocol (taking particular care to not allow the
tobacco companies to use lawyer involvement in the process as a
way to avoid disclosure) together with the raw data to reduce the
likelihood of the problems identified in this paper.
If one accepts PM’s assertion that Project MIX evaluated
additives in groups that ‘‘resemble typical commercial blended
cigarettes’’ [15], the data PM collected could be used for policy
making regarding the use of these 333 additives. That the Project
MIX scientists examined cigarette additives in combination (rather
than singly) allows for the possibility that the additives act either
synergistically or antagonistically. Allowing for this synergism is
important. A comparison of the estimated lung cancer effect of
tobacco smoke produced by summing the individual effects of
constituents of tobacco smoke produced an estimate of cancer risk
much smaller than the observed epidemiological risk [114].
Probably this is because all the carcinogens and cardiac toxins in
tobacco smoke have not been identified and because there are
likely interactions between the different constituents in the
complex mixture that cigarette smoke represents.
It is also important to emphasize that the definition of ‘‘harm’’
implicit in PM’s Project MIX and BAT’s similar experiments
[142–144]—direct short-term toxic effects of additives—is just one
dimension of the effects that additives have on disease. Additives
also have an effect on product palatability and pharmacologic
properties (Box 1) in ways that make cigarettes less harsh and more
pleasant to the user [3,151,152], leading to higher initiation and
lower cessation and, so, more tobacco use and tobacco-induced
disease [4,19]. Indeed, it was primarily on the basis of these
population-level impacts that the FDA Tobacco Products
Scientific Advisory Committee concluded that, ‘‘Removal of
menthol cigarettes from the marketplace would benefit public
health in the United States’’ [19].
Limitations
As noted in the Methods, this study is based on the documents
that PM made available as a result of litigation against the
company. While we were able to find several drafts and detailed
results of the Project MIX studies, that, for example, allowed us to
determine that the protocol for analyzing the data was altered after
the results indicating increased TPM were obtained, there are key
missing pieces of information: why PM chose the additives that
they did for study, as well as the levels and combinations and the
reason for selecting the sample sizes in the toxicology studies. This
situation represents a limitation of the available sources of
information and highlights the importance of the FDA using its
new authority to obtain all sources of data on additive testing and
other features of product manufacturing and testing and to make
them fully available for review.
Conclusion
The analysis in this paper shows that many of the toxins in
cigarette smoke increase substantially when additives are put in
cigarettes, including the level of TPM, and that, assuming that the
toxicological results from Project MIX represent unbiased
estimates of the true biological effects, these data show many
adverse biological consequences (and that the failure to reach
statistical significance was the result of underpowered studies
rather than lack of an effect). In particular, regulatory authorities,
including the FDA and similar agencies elsewhere who are
implementing FCTC articles 9–11, could use the Project MIX
data to eliminate the use of these 333 additives (including menthol,
which is the major component of ingredient group 3) in cigarettes.
Any tobacco company would, of course, remain free to submit
an application to the FDA, or other regulatory agency, to
reintroduce use of an additive if they could provide convincing
data from adequately powered studies that the additive truly did
not have any adverse health consequences.
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Background. The tobacco industry in the United States has
recognized that regulation of its products was inevitable as
early as 1963 and devoted increasing attention to the likelihood
of regulation by the US Food and Drug Administration in the
mid-1990s, which finally became law in 2009. In addition, the
World Health Organization (WHO) Framework Convention on
Tobacco Control (WHO FCTC), which came into force in June
2003, includes provisions addressing the regulation of the
contents of tobacco products and the regulation of tobacco
product disclosures. Although these stepsrepresent progress in
tobacco control, the events of the past few decades show the
determination of the tobacco industry to avoid regulation,
including the regulation of additives. In the United States,
executives of the tobacco company Philip Morris (PM)
recognized the inevitability of regulation and responded by
initiating efforts to shape legislation and regulation by
reorganizing its internal scientific activities and conducting
scientific research that could be used to shape any proposed
regulations. For example, the company conducted ‘‘Project
MIX,’’ a study of chemical constituents in and toxicity of smoke
produced by burning cigarettes containing three different
combinations of 333 cigarette additives that ‘‘were constructed
to resemble typical commercial blended cigarettes.’’ The
resulting four papers published in Food and Chemical
Toxicology in January 2002 concluded that there was no
evidence of substantial toxicity attributable to the cigarette
additives studied.
Why Was This Study Done? The use of cigarette additives
is an important concern of the WHO, FDA, and similar
national regulatory bodies around the world. Philip Morris
has used the published Project MIX papers to assert the
safety of individual additives and other cigarette companies
have done similar studies that reached similar conclusions. In
this study, the researchers used documents made public as a
result of litigation against the tobacco industry to investigate
the origins and design of Project MIX and to conduct their
own analyses of the results to assess the reliability of the
conclusions in the papers published in Food and Chemical
Toxicology.
What Did the Researchers Do and Find? The researchers
systematically examined tobacco industry documents in the
University of California San Francisco Legacy Tobacco
Documents Library (then about 60 million pages made
publicly available as a result of litigation) and used an
iterative process of searching, analyzing, and refining to
identify and review in detail 500 relevant documents.
The researchers found that in the original Project MIX
analysis, the published papers obscured findings of toxicity
by adjusting the data by total particulate matter (TPM)
concentration. When the researchers conducted their own
analysis by studying additives per cigarette (as was specified
in the original Project MIX protocol), they found that 15
carcinogenic chemicals increased by 20%. The researchers
also reported that, for unexplained reasons, Philip Morris
deemphasized 19 of the 51 chemicals tested in the
presentation of results, including nine that were substantially
increased in smoke on a per cigarette basis of additive-
added cigarettes, compared to smoke of control cigarettes.
The researchers explored the possibility that the failure
of Project MIX to detect statistically significant changes in
the toxicity of the smoke from cigarettes containing the
additives was due to underpowered experiments rather than
lack of a real effect by conducting their own statistical
analysis. This analysis suggests that a better powered study
would have detected a much broader range of biological
effects associated with the additives than was identified in
Philip Morris’ published paper, suggesting that it substan-
tially underestimated the toxic potential of cigarette smoke
and additives.
The researchers also found that Food and Chemical
Toxicology, the journal in which the four Project MIX papers
were published, had an editor and 11 of its International
Editorial Board with documented links to the tobacco
industry. The scientist and leader of Project MIX Edward
Carmines described the process of publication as ‘‘an inside
job.’’
What Do These Findings Mean? These findings show
that the tobacco industry scientific research on the use of
cigarette additives cannot be taken at face value: the results
demonstrate that toxins in cigarette smoke increase
substantially when additives are put in cigarettes. In
addition, better powered studies would probably have
detected a much broader range of adverse biological
effects associated with the additives than identified to
those identified in PM’s published papers suggesting that
the published papers substantially underestimate the toxic
potential combination of cigarette smoke and additives.
Regulatory authorities, including the FDA and similar
agencies elsewhere who are implementing WHO FCTC,
should conduct their own independent analysis of Project
MIX data, which, analyzed correctly, could provide a strong
evidence base for the elimination of the use of the studied
additives (including menthol) in cigarettes on public health
grounds.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001145.
N For PLoS Medicine’s own policy on publishing papers
sponsored by the tobacco industry see http://www.
plosmedicine.org/static/policies.action#funders
N The World Health Organization (WHO) provides informa-
tion on the Framework Convention on Tobacco Control
(FCTC)
N The documents that the researchers reviewed in this paper
can be found at the Legacy Tobacco Documents Library
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